In order to verify the validity of Cav3.2 as a therapeutic target for treatment of bladder pain, we evaluated the effect of novel T-type Ca2+ channel blockers and genetic deletion of Cav3.2 on the bladder pain in the mice with CPA-induced cystitis. Here, CACNA1H is linked to cystitis.